drugset / Trial / NCT07212062
The Purpose of This Study is to Evaluate the Safety and Tolerability of X/T+X-EC in Participants With Alzheimer's Disease Who Are Currently Treated With Lecanemab.
Phase 2
Not yet recruiting
60 enrolled
Neurology Office of South Florida
Bristol-Myers Squibb · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The goal of the trial is to see if the Safety and Tolerability of X/T+X/T-EC combined with currently treated Lecanemab participants with Alzheimer's Disease compared with placebo. This is a 32 week study (4 weeks of screening,24 weeks of treatment and 4 weeks of safety follow up)
Timeline
- Start
- 2025-12-01
- Primary completion
- 2028-04-01
- Completion
- 2028-12-30
Publications
- Background 20. Cobenfy (trospium-xanomeline). Package insert. Bristol-Myers Squibb Company; 2024.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Trospium | Small molecule | — | — |
| Comparator | Xanomeline | Small molecule | — | — |
| Comparator | Lecanemab | Monoclonal antibody | 10 mg/kg | — |